Literature DB >> 7703483

The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors.

F Hirayama1, S D Lyman, S C Clark, M Ogawa.   

Abstract

We have examined the effects of the murine ligand (FL) for the flt3/flk2 tyrosine kinase receptor on the proliferation of murine lymphohematopoietic progenitors as well as committed myeloid and B-cell progenitors. In the presence of erythropoietin, FL alone supported scant colony formation from enriched marrow cells of normal mice. However, when it was combined with interleukin-3 (IL-3), steel factor (SF), or IL-11, FL significantly enhanced colony formation. When tested on enriched marrow cells from 5-fluorouracil (5-FU)-treated mice, FL neither enhanced IL-3-dependent colony formation nor synergized with SF in support of colony formation. However, FL synergized with IL-6, IL-11, or granulocyte-colony stimulating factor (G-CSF) in support of formation of various types of colonies, including multilineage colonies. Approximately 30% of these colonies yielded pre-B-cell colonies when replated in secondary cultures containing SF and IL-7, indicating that 2-cytokine combinations, including FL and IL-6, IL-11, or G-CSF can support the proliferation of primitive lymphohematopoietic progenitors. FL, by itself and in synergy with IL-7 or SF, supported the proliferation of B-cell progenitors. These results show that FL has a wide range of activities in early hematopoiesis and B lymphopoiesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7703483

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Functional characterization of B lymphocytes generated in vitro from embryonic stem cells.

Authors:  S K Cho; T D Webber; J R Carlyle; T Nakano; S M Lewis; J C Zúñiga-Pflücker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non-self-renewing multipotent hematopoietic progenitor cells.

Authors:  Anna E Beaudin; Scott W Boyer; E Camilla Forsberg
Journal:  Exp Hematol       Date:  2013-12-11       Impact factor: 3.084

3.  Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells.

Authors:  J L Christensen; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

Review 4.  Bench to bedside targeting of FLT3 in acute leukemia.

Authors:  Keith W Pratz; Mark J Levis
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

5.  Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival.

Authors:  A Strasser; A G Elefanty; A W Harris; S Cory
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

6.  FLT3/ITD AML and the law of unintended consequences.

Authors:  Mark Levis
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

7.  Interleukin-7-induced Stat-5 acts in synergy with Flt-3 signaling to stimulate expansion of hematopoietic progenitor cells.

Authors:  Josefine Åhsberg; Panagiotis Tsapogas; Hong Qian; Jenny Zetterblad; Sasan Zandi; Robert Månsson; Jan-Ingvar Jönsson; Mikael Sigvardsson
Journal:  J Biol Chem       Date:  2010-09-09       Impact factor: 5.157

Review 8.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

9.  Hematopoietic stem and progenitor cells are differentially mobilized depending on the duration of Flt3-ligand administration.

Authors:  Evert-Jan F M de Kruijf; Henny Hagoort; Gerjo A Velders; Willem E Fibbe; Melissa van Pel
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

10.  Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6.

Authors:  Flavia Q Pirih; Megan N Michalski; Sun W Cho; Amy J Koh; Janice E Berry; Eduardo Ghaname; Pachiyappan Kamarajan; Edith Bonnelye; Charles W Ross; Yvonne L Kapila; Pierre Jurdic; Laurie K McCauley
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.